FDA Advisors Split on Regimens for Breast, Prostate Cancers

Published Date: 13 May 2026

The Oncologic Drugs Advisory Committee backed the prostate cancer drug but rejected a novel approach for breast cancer, highlighting challenges in defining clinical meaningfulness.

Read Full News

Latest News

Annual Cancer Report Highlights Advances, Funding Threats

A yearly report from the American Association for Cancer Research lauds recent breakthroughs but warns on threatened federal funding changes.

Does Telenursing Improve QOL in Breast Cancer?

A meta-analysis assesses the effect of nurse-led telenursing on the quality of life in women with breast cancer.

Long-Term Results Favor Acalabrutinib Combo in MCL

The 50-month follow-up of the ECHO trial underscores greater benefits with concurrent vs sequential addition of acalabrutinib to bendamustine and rituximab.

First-Line Combo Therapies Best Chemo Alone in NSCLC Trials

New phase 3 data add to a growing number of EGFR-directed first-line options for advanced NSCLC with EGFR exon 20 insertions.

3D Mammography Improves Long-Term Cancer Risk Prediction

Researchers develop and validate a deep learning model using longitudinal 3D tomosynthesis examinations to predict individualized 5-year risk for breast cancer.

Osimertinib's OS Benefit in Resected NSCLC Persists 8 Years

Even years after treatment ends, adjuvant osimertinib brings an overall survival benefit to patients with resected EGFR-mutated lung cancer.

Todays Updates

Solengepras Meets Primary Endpoint in Phase 3 ARISE Trial of Parkinson Disease Marco Meglio

Phase 3 ARISE trial results show solengepras 150 mg significantly reduced OFF time and improved motor and non-motor symptoms in Parkinson disease.

Upadacitinib Feasible for Palmoplantar Pustulosis: David Gleeson, BM BCH David Gleeson, BM BCH

Gleeson discusses JAKPPPOT data showing the therapy met all feasibility thresholds with a markedly larger response than historic placebo in PPP.

Nemolizumab Sustains Atopic Dermatitis Skin, Itch Control Through 3 Years

Nemolizumab Sustains Atopic Dermatitis Skin, Itch Control Through 3 Years

Atopic Dermatitis Pipeline and Remibrutinib Approval for Dermographism

Atopic Dermatitis Pipeline and Remibrutinib Approval for Dermographism

Todays Updates

Solengepras Meets Primary Endpoint in Phase 3 ARISE Trial of Parkinson Disease Marco Meglio

Phase 3 ARISE trial results show solengepras 150 mg significantly reduced OFF time and improved motor and non-motor symptoms in Parkinson disease.

Upadacitinib Feasible for Palmoplantar Pustulosis: David Gleeson, BM BCH David Gleeson, BM BCH

Gleeson discusses JAKPPPOT data showing the therapy met all feasibility thresholds with a markedly larger response than historic placebo in PPP.

Nemolizumab Sustains Atopic Dermatitis Skin, Itch Control Through 3 Years

Nemolizumab Sustains Atopic Dermatitis Skin, Itch Control Through 3 Years

Atopic Dermatitis Pipeline and Remibrutinib Approval for Dermographism

Atopic Dermatitis Pipeline and Remibrutinib Approval for Dermographism

Latest News

A yearly report from the American Association for Cancer Research lauds recent breakthroughs but warns on threatened federal funding changes.

A meta-analysis assesses the effect of nurse-led telenursing on the quality of life in women with breast cancer.

The 50-month follow-up of the ECHO trial underscores greater benefits with concurrent vs sequential addition of acalabrutinib to bendamustine and rituximab.

New phase 3 data add to a growing number of EGFR-directed first-line options for advanced NSCLC with EGFR exon 20 insertions.

Researchers develop and validate a deep learning model using longitudinal 3D tomosynthesis examinations to predict individualized 5-year risk for breast cancer.

Even years after treatment ends, adjuvant osimertinib brings an overall survival benefit to patients with resected EGFR-mutated lung cancer.

News All Time

Tissue-Free ctDNA Predicts Recurrence in Early Breast Cancer

Researchers analyzed plasma samples collected from 313 patients with early breast cancer approximately 2 years after they had completed adjuvant chemotherapy.

SBRT Plus Atezolizumab Shows No Benefit in Inoperable NSCLC

For patients with early-stage, inoperable lung cancer, adding atezolizumab to standard radiotherapy boosts toxicity, not survival.

TKI Discontinuation Feasible After ALL Treatment

In patients with first- or second-line Philadelphia-positive B-cell acute lymphoblastic leukemia, favorable outcomes are observed with discontinuation of ponatinib.

Sevabertinib Approved for First-Line Mutated NSCLC

The oral HER2 TKI was previously given accelerated approval in the second line for the indication.

A New PARADIGM? Azacitidine-Venetoclax Tops Chemo in AML

The less-intensive drug combination outperforms standard induction chemotherapy in fit patients with acute myeloid leukemia.

FDA Approves Camizestrant for ESR1-Mutated Breast Cancer

The accelerated approval enables an endocrine therapy switch when the ESR1 resistance mutation is detected, rather than waiting for evidence of disease progression.

Talc Powder Not Linked to Lung Cancer in Women

A study of US women finds no connection between talc powder use and lung cancer, though subgroup findings leave questions open.

Saturated Fat Tied to Worse Survival After Prostate Cancer

The association is driven by higher rates of death from cardiovascular disease and other cancers over 13 years.

Medication Self-Injection Embraced by Breast Cancer Patients

Women with breast cancer show interest in self-injecting their medication.

Can 80 Gy Radiation Boost Survival in Prostate Cancer?

A modest increase in radiation dose improves progression-free survival over 10 years among men with high-risk prostate cancer — but the overall survival benefits found in a French trial are uncertain.

Low Awareness of How to Spot Rare Breast Cancer Identified

Researchers survey US adults to assess their knowledge of inflammatory breast cancer.

Remote CBT for Insomnia Improves Symptoms During Chemo

A new randomized trial strengthens the case for managing cancer-related insomnia with cognitive-behavioral therapy.

Long-Acting Interferon Therapy Approved for ET

Ropeginterferon alfa-2b is designed to provide durable disease control.

Thymus Radiation Exposure Tied to Worse Lung Cancer Outcomes

The thymus is not routinely considered during thoracic radiotherapy planning, but new findings suggest that may need to change.

FDA Approves Rusfertide for Polycythemia Vera

Adding rusfertide to standard-of-care treatment cut phlebotomy rates by more than half in the phase 3 VERIFY trial.

Black Canadians Face Multiple Barriers to Blood Donation

Barriers to blood donations from Black people in Canada are rooted in racism and restrictive policies.

Recommended News For You

More pain, more gain? New biopsy technique found to improve prostate cancer detection

Can Oligonucleotide Infusions Really Fix Lyme, Cancer, and Other Diseases?

FDA Advisors Split on Regimens for Breast, Prostate Cancers

Temsirolimus Plus Chemotherapy Fails in Rare Childhood Cancer

UK government can save lives and smash inequalities by changing prostate cancer guidelines, say experts

A single bout of exercise gives results that could help cancer patients

improvements in the treatment of prostate cancer resistant to chemotherapy.

Recommended Articles For You

Digital Cancer Caregiver Coordination Platforms: Advances, Clinical Impact, and Future Directions 

Biomimetic Nanovesicles for Breast Cancer: Targeting Senescence to Overcome Chemoresistance 

Exploring the Potential of Cytologic Atypia in Cancer Diagnosis 

Precision Oncology: Integrating Genomics and Data to Shape Cancer Care’s Future 

Whats more on Hidoc Dr.

Medical Updates
KOL Videos
Surveys
Events

Daily news to keep you up to date

Gain valuable insights with our in-depth KOL Video discussions

Participate and win cash vouchers

Get updates on the latest events happening around the world
Featured News
Featured Articles
Featured Events
Featured KOL Videos

1.

Pancreatic cancer patients who were prescribed lorazepam for anxiety had poorer survival rates.

2.

According to a study, patients with ovarian cancer who undergo aggressive surgery have a 70% lower chance of dying.

3.

When Healthcare Chatbots Fall Short of Human Connection

4.

Even a few mutated cells can significantly impact how blood cancers develop, study finds

5.

Recently released national data on drug use and abuse among Americans.

1.

Understanding Bone Metastases: How Long Can Someone Live When Cancer Spreads To The Bones?

2.

The Ultimate Guide to Understanding Abiraterone and its Uses in Cancer Treatment 

3.

Lymphomatoid Papulosis: What You Need to Know

4.

Transforming Cancer Care: Metrics, Informatics, Equity, and Real-World Evidence

5.

Bone Marrow Immune Niche Remodeling in Hematopoiesis

1.

International Conference on Oncology, Cardiology and Critical Care Policy

2.

International Conference on Innovations in Critical Care for Oncology and Cardiology

3.

International Conference on Oncology, Cancer Prevention and Public Health

4.

International Conference on Cancer Nursing and Rehabilitation Strategies

5.

International Conference on Cancer Nursing and Hematology Support

1.

Breast Cancer Awareness and Early Detection

2.

Molecular Contrast: EGFR Axon 19 vs. Exon 21 Mutations - Part VII

3.

Revolutionizing Treatment of ALK Rearranged NSCLC with Lorlatinib - Part VII

4.

Common side effects of cancer treatment and how they are managed

5.

Targeting Oncologic Drivers with Dacomitinib: A New Approach to Lung Cancer Treatment

Fastest Growing Medical Platform for Doctors

Address :
Hidoc Dr. Inc. | Delaware C Corp | 1309 Coffeen Ave. Suite 1200, Sheridan WY, 82801

Phone :
+1-415-463-3094

Email :
anishagadia@hidoc.co

Quick Links

Drug DatabaseDrug InteractionDiseases Database
KOL VideosKnowledge HubQuizzes
Medical UpdatesEventsAbout Us

© Copyright 2026 Hidoc Dr. Inc.

Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation
Home
Profile
Login
bot